Holen Sie sich die Stockscreener-App
6.98
4.18%
0.28
Handel nachbörslich:
7.12
0.14
+2.01%
Schlusskurs vom Vortag:
$6.70
Offen:
$6.78
24-Stunden-Volumen:
506.25K
Relative Volume:
0.51
Marktkapitalisierung:
$464.87M
Einnahmen:
$80.00M
Nettoeinkommen (Verlust:
$-74.88M
KGV:
-5.9092
EPS:
-1.1812
Netto-Cashflow:
$-60.38M
1W Leistung:
+0.87%
1M Leistung:
-22.27%
6M Leistung:
-17.88%
1J Leistung:
+124.44%
1-Tages-Spanne:
$6.78
$7.16
1-Wochen-Bereich:
$6.56
$7.16
52-Wochen-Spanne:
$2.315
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.98 | 446.22M | 80.00M | -74.88M | -60.38M | -1.1812 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | JP Morgan | Overweight |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-07-29 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
S P Trends: What hedge funds are buying Fulcrum Therapeutics Inc2026 Big Picture & Real-Time Stock Entry Alerts - baoquankhu1.vn
Institution Moves: Is Fulcrum Therapeutics Inc forming higher highs and higher lows2026 Earnings Surprises & Weekly Market Pulse Updates - baoquankhu1.vn
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Growth Value: What hedge funds are buying Fulcrum Therapeutics IncMarket Sentiment Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Profit Recap: Can Fulcrum Therapeutics Inc deliver alpha2026 Retail & Weekly Return Optimization Alerts - baoquankhu1.vn
Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study - TipRanks
Is Fulcrum Therapeutics Inc benefiting from innovation trends2026 Closing Moves & Stepwise Swing Trade Plans - baoquankhu1.vn
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease - The Manila Times
MedicAlert Foundation, Sickle Cell Disease Association of - GlobeNewswire
Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk - MarketBeat
Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Rises By 19.7% - MarketBeat
Boothbay Fund Management Increases Stake in Fulcrum Therapeutics - National Today
Fulcrum Therapeutics, Inc. $FULC Shares Bought by Boothbay Fund Management LLC - MarketBeat
Wall Street analysts think Fulcrum Therapeutics (FULC) could surge 58.47%: Read this before placing a bet - MSN
219,488 Shares in Fulcrum Therapeutics, Inc. $FULC Bought by Braidwell LP - MarketBeat
Suvretta Capital Management LLC Raises Holdings in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Whats next for Fulcrum Therapeutics Inc stock2026 Winners & Losers & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Aug Macro: What’s next for Fulcrum Therapeutics Inc. stock2026 EndofYear Setup & Free Verified High Yield Trade Plans - baoquankhu1.vn
Fulcrum Therapeutics at Leerink Conference: Strategic Focus on Sickle Cell - Investing.com India
Fulcrum Therapeutics at Leerink Conference: Strategic Focus on Sickle Cell By Investing.com - Investing.com Canada
FULC: Pivotal study planned after robust PIONEER results, with focus on severe sickle cell and U.S. launch - TradingView
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Fulcrum Therapeutics (FULC) Stock Analysis Report | Financials & Insights - Benzinga Japan
Fulcrum Therapeutics stock may face pressure on Ipsen withdrawal, Stifel says - Investing.com Canada
Why Fulcrum Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Highlights & Daily Price Action Insights - Naître et grandir
Bullish analyst sentiment on Fulcrum Therapeutics (FULC) following positive updates from Phase 1b PIONEER study - MSN
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bull Run: Can Fulcrum Therapeutics Inc disrupt its industryJuly 2025 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
New Fulcrum hire gets 34,000 stock options with 4-year vesting - Stock Titan
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - 富途牛牛
Hedge Fund Moves: Is Fulcrum Therapeutics Inc part of any ETFJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
FULC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 7.5%Here's Why - MarketBeat
FULC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Winners Losers: Can Fulcrum Therapeutics Inc keep up with sector leadersBond Market & Stepwise Swing Trade Plans - baoquankhu1.vn
What is HC Wainwright’s Forecast for FULC Q1 Earnings? - Defense World
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion (NASDAQ:FULC) - Seeking Alpha
Fulcrum Therapeutics, Inc. (FULC): Analyst Ratings Suggest 111% Upside Potential – Is It Time to Buy? - DirectorsTalk Interviews
HC Wainwright Has Optimistic Outlook of FULC Q1 Earnings - MarketBeat
RBC Capital Remains a Hold on Fulcrum Therapeutics (FULC) - The Globe and Mail
FY2030 Earnings Forecast for FULC Issued By HC Wainwright - Defense World
Fulcrum Therapeutics move lower ‘overdone,’ says Stifel - Yahoo Finance
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Fulcrum Therapeutics stock falls as sickle cell trial misses target - Investing.com Australia
Fulcrum Therapeutics stock falls as sickle cell trial misses target By Investing.com - Investing.com Canada
Leerink reiterates Fulcrum Therapeutics stock rating on SCD data By Investing.com - Investing.com Canada
Fulcrum Therapeutics shares fall on profit-taking, Oppenheimer says By Investing.com - Investing.com Canada
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):